The present invention generally relates to a method of using NMR relaxation rates of water molecules as an indicator of the extent of aggregation of biopharmaceutical formulations. The device comprises a plurality of hardware components, a plurality of functional modules, an input device, and a processing module. The active display overlay unit can be capable of providing full-color luminance of at least t 1200 fL to the ocular of the host system with a luminance to power fL:mW ratio of at least 6:1 or greater or providing monochrome luminance from the active display overlay unit of at least 5000 fL to the ocular of the host system with a luminance to power fL:mW ratio of at least 15:1 or greater.